Cansino Biologics Inc (688185) - Total Liabilities

Latest as of December 2025: CN¥-4.93 Billion CNY ≈ $-721.61 Million USD

Based on the latest financial reports, Cansino Biologics Inc (688185) has total liabilities worth CN¥-4.93 Billion CNY (≈ $-721.61 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cansino Biologics Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Cansino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See 688185 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Cansino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of Cansino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Eton Pharmaceuticals Inc NASDAQ:ETON	USA	$67.09 Million
Sagicor Financial Company TO:SFC	Canada	CA$23.66 Billion
Grupo Posadas S.A.B. de C.V MX:POSADASA	Mexico	MX$17.92 Billion
Anpec Electronics TWO:6138	Taiwan	NT$1.74 Billion
Sun Pharma Advanced Research Company Limited NSE:SPARC	India	Rs6.67 Billion
Apotea ST:APOTEA	Sweden	Skr1.28 Billion
Eczacibasi Yatirim Holding Ortakligi AS IS:ECZYT	Turkey	TL573.72 Million
D-MARKET E.S.+T.SP.ADR/1B F:8WZ	Germany	€34.93 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Cansino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688185 stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.00	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	-0.69	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cansino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cansino Biologics Inc (2016–2025)

The table below shows the annual total liabilities of Cansino Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	CN¥-4.93 Billion ≈ $-721.61 Million	-261.78%
2024-12-31	CN¥3.05 Billion ≈ $446.06 Million	-24.39%
2023-12-31	CN¥4.03 Billion ≈ $589.91 Million	-4.55%
2022-12-31	CN¥4.22 Billion ≈ $618.01 Million	+26.97%
2021-12-31	CN¥3.33 Billion ≈ $486.74 Million	+391.17%
2020-12-31	CN¥677.22 Million ≈ $99.10 Million	+115.69%
2019-12-31	CN¥313.98 Million ≈ $45.95 Million	+6.96%
2018-12-31	CN¥293.56 Million ≈ $42.96 Million	+13.33%
2017-12-31	CN¥259.03 Million ≈ $37.90 Million	+131.90%
2016-12-31	CN¥111.70 Million ≈ $16.35 Million	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$835.65 Million

CN¥5.71 Billion CNY

Market Cap Rank

#9868 Global

#2630 in China

Share Price

CN¥49.93

Change (1 day)

+0.34%

52-Week Range

CN¥49.41 - CN¥88.48

All Time High

CN¥773.75